LIC Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹200
Lumpsum amount
Min. ₹5,000

LIC Healthcare IDCW Reinvest Direct Plan

NAV
₹32.3986
+0.21%
(19 Aug)
AUM
91 Cr
TER
1.22%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+8.5%
-4.5%
-4.5%
-4.5%
-5.0%
3Y
+21.3%
+32.6%
+32.6%
+32.6%
+32.1%
5Y
+15.9%
+31.3%
+31.3%
+31.3%
+29.2%
ALL
+19.9%
+11.8%
+11.8%
+11.8%
+16.5%
VOL
15.9%
20.2%
20.2%
20.2%
20.3%
TER
1.2%
0.8%
0.8%
0.8%
0.9%
AUM
₹91 Cr
₹5,278 Cr
₹5,278 Cr
₹5,278 Cr
₹1,391 Cr
INFO
1.25
0.58
0.58
0.58
0.82
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
LIC Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Jul
Top holdings
Sun Pharmaceuticals Industries Ltd
10.1%
Apollo Hospitals Enterprise Ltd
5.5%
Torrent Pharmaceuticals Ltd
5.4%
Cipla Ltd
5.3%
Treps
4.5%
Divi's Laboratories Ltd
4.5%
Fortis Healthcare Ltd
4.0%
Aurobindo Pharma Ltd
3.9%
Piramal Pharma Ltd
3.7%
Abbott India Ltd
3.7%
Top industry exposure
Healthcare
88.6%
Basic Materials
7.0%
Other information
Minimum SIP
₹200
Minimum lumpsum
₹5,000
Additional lumpsum
₹500
Portfolio turnover
46%
Lock-in period
-
Exit load
• 1% for redemption within 90 days
Fund objective
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.
Fund manager(s)
Karan Doshi

FAQs